At a glance
- Originator Bristol-Myers Squibb
- Class Indoles; Obesity therapies; Small molecules
- Mechanism of Action Serotonin 2C receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 18 Jan 2008 Discontinued - Preclinical for Obesity in USA (PO)
- 17 Dec 2003 No development reported - Preclinical for Obesity in USA (PO)
- 23 Apr 2001 Preclinical development for Obesity in USA (PO)